Stolt-Nielsen Limited Announces Intention to Relaunch Share Buy-Back Programme
LONDON, April 3, 2025 - Stolt-Nielsen Limited ( Oslo Børs: SNI ) announced today that it intends to continue the share buy-back programme announced on March 2, 2016. Under the 2016 buy-back programme, the Board of Directors had authorised the purchase of up to $30 million worth of the Company's ...
'Absolutely nothing good' coming out of Trump's tariff announcement: Analysts react to latest U.S. levies
Analysts generally had a pessimistic take on the announcement, with some even predicting an increased risk of a recession for the U.S.
Private equity firms urge UK to rethink carried interest tax change
Blackstone, KKR and EQT among buyout groups raising concerns over government reforms ...
Stablecoin Transparency Bill Passes House Committee With Overwhelming Vote
The STABLE Act has cleared the House Financial Services Committee, even as scrutiny of Trump-linked stablecoin ventures mounts.
ByteDance, Alibaba, And Tencent Order $16 Billion Worth Of Nvidia's H20 Chips As Demand Surges For DeepSeek's Low-Cost AI Models: Report - Alibaba Gr Hldgs ( NYSE:BABA ) , NVIDIA ( NASDAQ:NVDA )
Chinese tech giants ByteDance, Alibaba Group BABA, and Tencent Holdings TCEHY have reportedly placed over $16 billion in orders for Nvidia Corporation's NVDA H20 server chips in the first quarter of 2025.
Explainer | After Trump's 'Liberation Day', what's China's effective tariff rate?
With US 'reciprocal tariffs', taxes on Chinese goods have climbed even further - with some analysts predicting an effective rate of 'almost 70 per cent'.
Tallinna Sadam audited Annual Report 2024 and dividend proposal
The supervisory board of AS Tallinna Sadam ( hereinafter: "Tallinna Sadam" ) approved the audited annual report for 2024 presented by the management board. Compared to the unaudited interim report published on 28 February, there are no differences in the audited financial results.
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...
